GlassScriptPhysician profile
Jeffrey V Wilde
NPI 1073703310
$4,987.35
in general payments reported to CMS, 2019-2025
40 companies · $662 in 2025
The $662 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $526 · 2021: $1,136 · 2022: $831 · 2023: $772 · 2024: $687 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.96 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $519.83 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $475.32 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $467.89 | 2019-2025 | Airsupra, Breztri, Byetta |
| Novo Nordisk INC | $443.13 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $271.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $268.32 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $230.64 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $180.33 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.21 | 2019-2025 | Xifaxan, Trulance |
| Sunovion Pharmaceuticals INC. | $126.67 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $125.86 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.06 | 2019-2021 | |
| Abbott Laboratories | $87.45 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $74.79 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wilde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.